65,437 trials
Myelodysplastic Syndrome · Acute Myelogenous Leukemia
Primary: Number of Participants With Response — 12; 3; 7 Participants
Influenza · Swine-origin A/H1N1 Influenza
Primary: Number of Participants With Antibody Titers ≥ 10 1/Dilution (1/Dil) Against A/California (H1N1 Vaccine) Strain - Age 18 to 64 Years — 69; 70; 61; 23 Participants
Untreated Childhood Anaplastic Astrocytoma · Untreated Childhood Anaplastic Oligodendroglioma · Untreated Childhood Brain Stem Glioma
Primary: Number of Participants in Phase I Stratum 1A With Dose-limiting Toxicities (DLT) Observed During the First 8 Weeks of Gefitinib Therapy — 2; 0; 1 Participants
HIV Infections · HIV-1 · Human Immunodeficiency Virus Type 1
Primary: Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies/ml) at Week 48 — 287; 285; 38; 15 Participants…
Sensorineural Hearing Loss
Primary: Participants Whose Change in Percent Correct Word Recognition Scores From Baseline to One Week After Study Treatment Equalled or Exceeded the Minimum Change in a…
Intrauterine Device Expulsion · Medical Abortion · Induced Abortion
Primary: Percentage of Women With Expulsion of an Intrauterine Device (IUD) Placed After Medical Abortion. — 4 percentage of participants
Chronic Sinusitis
Primary: Number of Sinuses With Patency of Sinus Ostium After Sinuplasty — 247 Sinuses
Thyroid Neoplasms
Primary: Time to Tumor Progression — 334; 176 days
Skin and Soft Tissue Infections
Primary: Clinical Efficacy — 2; 0 participants
Parkinson's Disease
Primary: Change in Parkinson's Disease Questionnaire-39 Single Index Score (PDQ-39SI)From Baseline to Study Endpoint of 11 Months — 4.96 scores on a scale
NSCLC
Primary: Progression-free Survival (PFS) Rate at 3 Months — 28; 12 Participants
Complicated Skin and Skin Structure Infections · Complicated Intra-abdominal Infections
Primary: Number of Participants With Spontaneous Adverse Events — 17 Participants
Meningococcal Disease
Primary: Geometric Mean Titer of the Meningococcal B Vaccine Against the Different Strains at One Month After First, Second and Third Vaccination. — 2.5; 2.3; 1.8; 33 titer
Kidney Transplantation
Primary: Patient Incidence of Biopsy-confirmed Acute Rejection (BCAR) at 6 Months — 6.2; 9.4; 1.9; 17.5 Percentage of Patients — p=0.4889
Parkinson's Disease
Primary: Change From Baseline to Study End Point in the Combined Scores From the UPDRS Subscale II and III Recorded in the Subjects "on" State. — -1; -5 scores on a scale